poisar

Stocks · News reference

Lake Street Initiates Coverage of AbCellera Biologics with Buy Rating

Fiscal.ai

Analyst Daniel Brims at Lake Street has initiated coverage on AbCellera Biologics with a 'Buy' rating and a price target of $19.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    AbCellera Biologics Q3 2026 Earnings Call Transcript

    AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga